Cel­cu­ity has pro­vid­ed fur­ther de­tails on why the com­mer­cial roll­out of its re­cent­ly ap­proved can­cer drug is slow­er than in­vestors ini­tial­ly an­tic­i­pat­ed.

The drug­mak­er said...

Sev­en large drug­mak­ers and lob­by­ing groups PhRMA and BIO have called up­on the Ger­man gov­ern­ment to re­vise some of its new drug pric­ing poli­cies as...

As­traZeneca on Mon­day re­port­ed suc­cess­es in two late-stage tri­als in dif­fer­ent forms of lung can­cer — one with a two-drug com­bi­na­tion of Tagris­so and Or­pa­thys...

As­traZeneca has end­ed a Phase 3 study of one of its can­cer drugs, the lat­est in a string of set­backs the drug­mak­er has en­dured.

The...

Sum­mit Ther­a­peu­tics and Ake­so’s next-gen­er­a­tion can­cer drug ivonescimab earned an ap­proval in Chi­na last week for first-line pa­tients with cer­tain forms of lung can­cer. But it...

Eye­Point’s ex­per­i­men­tal eye treat­ment came up short of Eylea, the cur­rent go-to op­tion for wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, ac­cord­ing to re­sults of a Phase 3...